Showing results (221-230 of 341) with videos related to
Sort By:
Pageof 35
The Lancet. Diabetes & Endocrinology|December 3, 2021
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trialSubodh Verma, Nitish K Dhingra, Javed Butler, et al.The New England Journal of Medicine|May 24, 2008
Bivalirudin during primary PCI in acute myocardial infarctionGregg W Stone, Bernhard Witzenbichler, Giulio Guagliumi, et al.Journal of the American College of Cardiology|March 23, 2019
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-ITDeepak L Bhatt, Ph Gabriel Steg, Michael Miller, et al.JAMA Network Open|April 21, 2026
Invasive vs Conservative Strategy for Frail Older Patients With Myocardial Infarction: A Secondary Analysis of the SENIOR-RITA Randomized Clinical TrialFrancesca Rubino, Helen Mossop, David P Ripley, et al.The American Journal of Cardiology|October 13, 2004
Impact of anemia on outcomes of patients undergoing percutaneous coronary interventionsEugenia Nikolsky, Roxana Mehran, Eve D Aymong, et al.European Heart Journal|June 29, 2021
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trialCarolyn S P Lam, João Pedro Ferreira, Egon Pfarr, et al.American Heart Journal|April 24, 2023
Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: Insights from a large PCI registryAlessandro Spirito, Won-Joon Koh, Samantha Sartori, et al.Annals of Neurology|April 29, 2009
Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trialAllan H Ropper, Kenneth C Gorson, Clifton L Gooch, et al.Circulation. Cardiovascular Quality and Outcomes|January 5, 2019
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding RiskUsman Baber, Daniel E Leisman, David J Cohen, et al.Journal of the American Heart Association|December 24, 2022
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic CauseMuhammad Shahzeb Khan, Javed Butler, Stefan D Anker, et al.Pageof 35